Daxor (DXR) vs Pulmonx (LUNG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pulmonx (LUNG) has outperformed Daxor (DXR) over the past year, gaining 1.7% versus a loss of 21.9%. Over five years, DXR leads with a -6.6% price change compared with -95.5% for LUNG. Pulmonx is the larger company by market cap ($77.7 million vs $61.1 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | LUNG |
|---|---|---|
| Share price | $10.46 | $1.81 |
| Market cap | $61.07M | $77.74M |
| 1-day change | +1.01% | -1.63% |
| YTD return | -28.75% | -18.10% |
| 1-year return | -21.86% | +1.69% |
| 5-year return | -6.58% | -95.45% |
| P/E ratio (TTM) | 9.60 | — |
| EPS (TTM) | $1.09 | $-1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $2.89 |
| 52-week low | $8.56 | $1.13 |
| Distance from 52-week high | -29.13% | -37.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +91.20% | +87.85% |
| Average volume | 17.23K | 477.26K |
| Shares outstanding | 5.84M | 42.95M |
| Employees | — | 296 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed DXR by 23.5 percentage points over the past year.
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Healthcare · Medical Instruments & Supplies
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Healthcare · Medical Devices · 296 employees
DXR vs LUNG FAQ
Which is bigger, Daxor or Pulmonx?
Pulmonx (LUNG) is larger, with a market capitalization of $77.74M compared with $61.07M for Daxor (DXR).
Which stock has performed better over the past year, DXR or LUNG?
LUNG returned +1.69% over the past 12 months, compared with -21.86% for DXR (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and Pulmonx in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Instruments & Supplies for Daxor and Medical Devices for Pulmonx.